Literature DB >> 2459531

Amiodarone causes acute oxidant lung injury in ventilated and perfused rabbit lungs.

T P Kennedy1, G B Gordon, A Paky, A McShane, N F Adkinson, S P Peters, K Friday, W Jackman, A M Sciuto, G H Gurtner.   

Abstract

Amiodarone (ADR), a new antiarrhythmic drug for life-threatening cardiac arrhythmias, causes pneumonitis or lung fibrosis in a sizeable minority of patients. The cause of lung damage is not known. We have shown that infusion of 10 mg amiodarone into the inflow circuit of ventilated and perfused rabbit lungs causes immediate increase in pulmonary artery pressure (mean +/- SEM) (from 13.6 +/- 1.2 to 40.6 +/- 9.5 mm Hg, p less than 0.01) and pulmonary edema with marked increase in the pulmonary generation of thromboxane and leukotrienes C4 and/or D4. Albumin (2 g%) in the perfusate prevents any increase in lung perfusion pressure or edema formation. When lung perfusion pressure increase is blocked with the combined cyclooxygenase and lipoxygenase inhibitor enolicam sodium (CG5391B, 35 microM in perfusate), significant lung edema still occurs after amiodarone, indicating that amiodarone causes increased alveolar-capillary membrane permeability. Addition of catalase (100 U/ml) or superoxide dismutase and catalase (100 U/ml each) to perfusate fails to protect from amiodarone lung injury. Immediate infusion of amiodarone (10 mg) into lungs ventilated with room air (ADR + RA) causes an increase in lung weight gain from baseline (delta W) of 5.7 +/- 1.5 g/min. Compared with ADR + RA, ventilation of lungs with 4% O2 (delta W = 0.7 +/- 0.3 g/min, p less than 0.05), pretreatment of rabbits for 3 days with butylated hydroxyanisole (BHA, 100 mg/kg/day i.p., delta W = 0.05 +/- 0.02 g/min, p less than 0.01), pretreatment of rabbits for 3 days with vitamin E (Vit E, 300 U/day orally, delta W = 0.6 +/- 0.2 g/min, p less than 0.05), or addition of N-acetylcysteine to the lung perfusate (NAC, 5 mM, delta W = 0.1 +/- 0.08 g/min, p less than 0.01) all protect from lung edema formation after amiodarone. Amiodarone (100 mg) also caused a marked increase in luminol-enhanced lung chemiluminescence, lung production of superoxide anion (O2-), and tissue levels of lung glutathione disulfide. These results suggest that amiodarone causes lung injury by an oxidant mechanism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459531     DOI: 10.1097/00005344-198807000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Transient Blockade of Endothelin-1 Mitigates Amiodarone-Induced Pulmonary Fibrosis.

Authors:  Xingjian Liu; Nikhil Khadtare; Hardek Patel; Ralph Stephani; Jerome Cantor
Journal:  Lung       Date:  2018-03-07       Impact factor: 2.584

2.  Ibuprofen prevents oxidant lung injury and in vitro lipid peroxidation by chelating iron.

Authors:  T P Kennedy; N V Rao; W Noah; J R Michael; M H Jafri; G H Gurtner; J R Hoidal
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

Review 3.  Antioxidants as potential therapeutics for lung fibrosis.

Authors:  Brian J Day
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

4.  Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats.

Authors:  Durairaj Punithavathi; Narayanan Venkatesan; Mary Babu
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

5.  Ultrastructural Changes in Rat's Atrial Cardiomyocytes After Short Term Administration of Amiodarone and Possible Protective Role of Vitamin E.

Authors:  Abdullah S Shatoor; Mohamed Samir Ahmad Zaki; Refaat A Eid; Mohamed A Sayed-Ahmad
Journal:  J Clin Med Res       Date:  2012-05-15

6.  Attenuation of amiodarone induced lung fibrosis and phospholipidosis in hamsters, by treatment with the platelet activating factor receptor antagonist, WEB 2086.

Authors:  S N Giri; D M Hyde; D R Haynam; M Casias
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.